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Alzheimer diseaseGlobal obesity is a pandemic status, estimated to affect over 2 billion people, that has resulted in an enormous
strain on healthcare systems worldwide. The situation is compounded by the fact that apart from the direct
costs associated with overweight pathology, obesity presents itself with a number of comorbidities, including
an increased risk for the development of neurodegenerative disorders. Alzheimer disease (AD), the main cause
of senile dementia, is no exception. Spectacular failure of the pharmaceutical industry to come up with effective
AD treatment strategies is forcing the broader scientiﬁc community to rethink the underlying molecular mecha-
nisms leading to cognitive decline. To this end, the emphasis is once again placed on the experimental animal
models of the disease. In the current study, we have focused on the effects of a high-fat diet (HFD) on
hippocampal-dependent memory in C57/Bl6 Wild-type (WT) and APPswe/PS1dE9 (APP/PS1) mice, a well-
established mouse model of familial AD. Our results indicate that the continuous HFD administration starting
at the time of weaning is sufﬁcient to produce β-amyloid-independent, hippocampal-dependent memory
deﬁcits measured by a 2-object novel-object recognition test (NOR) inmice as early as 6 months of age. Further-
more, the resulting metabolic syndrome appears to have direct effects on brain insulin regulation and mitochon-
drial function. We have observed pathological changes related to both the proximal and distal insulin signaling
pathway in the brains of HFD-fed WT and APP/PS1 mice. These changes are accompanied by a signiﬁcantly
reduced OXPHOS metabolism, suggesting that mitochondria play an important role in hippocampus-dependent
memory formation and retention in both the HFD-treated and AD-like rodents at a relatively young age.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Over the last couple of decades a global nutrition transition from
undernourishment to overconsumption has taken place. Replacement
of traditional diets with cheap and easily available processed foodsi Farmacognosia, Facultat de
643, E-08028 Barcelona, Spain.rich in reﬁned carbohydrates, animal fats and edible oils resulted in a
global obesity pandemic. While usually considered the plight of the
developed world, obesity is also an emerging public health concern
among the growing middle classes in poorer countries [1]. Overweight
and moderate obesity (deﬁned as Body Mass Index (BMI) of between
25 and 35) may not have a major impact on life expectancy per se [2],
however, excessive weight signiﬁcantly increases the risks of develop-
ing a number of pathological conditions. These include metabolic
syndrome, diabetes, non-alcoholic steatohepatitis, coronary heart dis-
ease, stroke, gallbladder disease, osteoarthritis, some types of cancers
[3], cognitive decline and Alzheimer disease (AD) [4–7].
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between 60 and 80% of all dementias. According to recent estimates,
the number of cases of AD worldwide is projected to rise from approx-
imately 30 million in 2010 to 40 million by 2020 and to 100 million by
2050. Apart from the genetic component and old age, seven primary
preventable environmental risk factors contributing to AD have been
identiﬁed: diabetes mellitus, midlife hypertension, midlife obesity,
depression, physical inactivity, smoking and cognitive inactivity [8,9].
Thus, it is becoming increasingly evident that most of the prognostic
preventable AD risk factors may also be linked to obesity and resulting
comorbidities, including metabolic syndrome and diabetes. Even
though the epidemiological data suggest an existing relationship
between AD and energy metabolism, molecular mechanisms behind
this relationship are poorly understood. Because AD is a multifactorial
disorder with complex etiology which takes decades to fully develop,
it is especially challenging to identify the precise disease mechanisms.
For example, in a patient with dementia it is not always easy to tell if
the underlying pathology is that of a speciﬁc brain disease or whether
it is also associated with vascular components, metabolic alterations
or additional factors (ie. traumatism). Such difﬁculties notwithstanding,
recent years saw a number of breakthroughs in AD research ﬁeld which
contribute to a greater understanding of themolecular dynamics of this
devastating condition.
A classical, but currently hotly debated “amyloid cascade” hypothe-
sis [10,11] states that cognitive decline and memory loss in AD are
caused by the formation of large, insoluble beta amyloid plaques in
the brain, which result in neuronal death and produce characteristic
disease symptoms. However, it is necessary to differentiate between
the insoluble plaques and soluble amyloidmolecules. Recently emerged
alternative theories suggest that the β-amyloid monomers, ﬁbrils, or
oligomers, and not the plaques, may in fact be the primary neurotoxic
species in the brain, responsible for AD development and progression
[12]. Apart from amyloid beta itself, mounting evidence suggests that
impaired glucose and insulin signaling and metabolism in the brain
play a key role in AD. The discovery of brain-speciﬁc insulin signaling
deﬁciencies in the very early stages of AD pathogenesis has led some
authors to propose that AD may be termed “type 3 diabetes” [13–15].
This hypothesis is further strengthened by a recent study of diabetes-
related genes in the brains of post-mortem AD patients and in a
mouse model of AD [16]. Microarray analysis has demonstrated signiﬁ-
cant alterations in the mRNA expression proﬁles of genes related to
insulin signaling, obesity and diabetes in the frontal cortex, temporal
cortex and hippocampus in both species. Interestingly, the biggest dif-
ferences were observed in the hippocampus, a key area related to
memory.
Deﬁciencies in Tauprocessingmay provide yet another link between
diabetes and AD. Hyperphosporylated Tau protein is a principle constit-
uent of neuroﬁbrillary tangles (NFT) [17]which, alongside amyloid beta
plaques, have long been considered key histopathological hallmarks of
AD. Abnormalities in Tau phosphorylation have been detected in cortex
and the hippocampi of both type 1 (streptozotocin-induced) and type 2
(db/db) mouse models of diabetes [18,19].
Prior research has established a clear relationship between obesity,
insulin resistance, diabetes and dementia (reviewed in [20]). Results
from published research indicate that there is a close link between insu-
lin deﬁcient diabetes and cerebral amyloidosis in the pathogenesis of
AD [21–24]. Epidemiological, clinical, and basic studies have shown a
relationship between AD and Type 2 Diabetes Mellitus (T2DM), and
that the main physiological link between both conditions is peripheral
and central insulin signalling impairment [25,26]. In fact, results from
the so called “Hysayama Study” indicate that altered expression of
genes related to diabetes mellitus in AD brains is a result of AD pathol-
ogy, whichmay thereby be exacerbated by peripheral insulin resistance
or diabetes mellitus [16]. These cognitive deﬁcits associated to T2DM
have been argued to be due in large part to an impaired central insulin
modulation in the hippocampus, which is a critical region for memoryprocessing [27]. Furthermore, a number of recent pilot clinical trials
have demonstrated an improvement in AD symptoms in patients
upon administration of both the intranasal insulin and Glucagon-like
peptide-1 (GLP1) analogues. It has been suggested that these com-
poundsmay affect synaptogenesis, neurogenesis, cell repair and inﬂam-
mation processes, and may additionally help to reduce cerebral β-
amyloid load (reviewed in [28]).
As it is especially difﬁcult to study long-term effects of hypercaloric
diet in human subjects, we have chosen a mouse model in order to
further investigate the underlying molecular events linking brain ener-
gy metabolism to AD. A well-established experimental approach to
induce insulin resistance in peripheral organs of rodents consists of a
high-fat diet (HFD) treatment, which results in obesity [29–31].
We have characterized the neuropathological effects of a HFD in 6-
months-old male APPswe/PS1dE9 (APP/PS1) mice in comparison to
the nontransgenic C57BL/6 (non-Tg; WT) control animals.
2. Materials and methods
2.1. Animals
Male APPswe/PS1dE9 and C57BL/6 mice were used in this study.
APP/PS1 animals co-express a Swedish (K594M/N595L) mutation of a
chimeric mouse/human APP (Mo/HuAPP695swe), together with the
human exon-9-deleted variant of PS1 (PS1-dE9), allowing these mice
to secrete elevated amounts of human Aβ peptide. Both mutations are
associated with AD, are under control of the mouse prion protein
promoter, directing both mutated proteins mainly to the CNS neurons,
and result in age-dependent amyloid plaque depositions in mouse
brain. The APPswe-mutated APP is a favorable substrate for β-
secretase, whereas the PS1dE9 mutation alters β-secretase cleavage,
thereby promoting overproduction of Aβ42. The mice were fed for
5 months with a high-fat diet consisting of 25% fat (45 kcal %), mainly
from hydrogenated coconut oil, 21% protein (16 kcal %), and 49% carbo-
hydrate (39 kcal %); Cat# D08061110 (Research Diets Inc, New Bruns-
wick, USA). Body weight was recorded weekly. The animals were kept
under controlled temperature, humidity and light conditions with
food and water provided ad libitum. Mice were treated in accordance
with the European Community Council Directive 86/609/EEC and the
procedures established by the Department d'Agricultura, Ramaderia i
Pesca of the Generalitat de Catalunya. Every effort was made to mini-
mize animal suffering and to reduce the number of animals used. Fifty
animals, divided into four groups, were used for the present study,
with at least 10 wild-type and 10 6-month-old APP/PS1 transgenic
mice, per group. Following in vivo testing, the animals were sacriﬁced
at the age of 6 months and at least 6 mice in each group were used for
RNA and protein extract isolation, with an additional 4 mice used for
immunoﬂuorescence.
2.2. Total blood cholesterol and triglycerides measurements
Total blood cholesterol and triglyceride levels were measured
following 4-hour-long fast at the point of sacriﬁce with Accutrend Plus
meter (Roche Diagnostics, Switzerland).
2.3. Glucose and insulin tolerance tests
Intraperitoneal glucose tolerance tests (IP-GTT) and insulin toler-
ance tests (ITT) were performed in accordance with the previously
published guidelines [32]. For IP-GTT, mice were fasted overnight for
16 h. The test was performed in a quiet room, preheated to +30 °C.
The tip of the tail was cut with the heparin-soaked (Heparina Rovi,
5000 IU/ml; Rovi S.A.;Madrid, Spain) scissors, 30 min prior to 1 g/kg
intraperitoneal glucose injection (diluted in H2O). Blood glucose levels
in the tail vein were measured at −30, 0, 5, 15, 30, 60 and 120 min
after the glucose injection with the Ascensia ELITE blood glucose
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performed in similar conditions with the 0.25 IU/kg of human insulin,
diluted in saline (Humulina Regular, 100 IU/ml/Lilly, S.A.;Madrid,
Spain), except that the mice underwent a 4-5 hour-long morning fast.
Blood glucose levels were measured at−30, 0, 15, 30, 45 and 60 min
after the insulin administration. If during this time blood glucose levels
dropped to below 20 mg/dl, 1 g/kg glucose was administered to coun-
teract the effects of insulin, in order to reduce animal suffering.2.4. 2-Object novel object recognition test (NOR)
The test was conducted as previously described by us and others
[33]. In brief, a 90°, 25 cm long, and 20 cm high L maze was used. The
light intensity in the middle of the ﬁeld was 30 lx. The objects to be
discriminated were plastic ﬁgures (object A: 5.25 cm high, object B:
4.75 cm high). First, mice were individually habituated to the apparatus
for 10min a day, for two days. On the third day, they were submitted to
a 10 min acquisition trial (ﬁrst trial) during which they were placed in
the maze in the presence of two identical novel objects (A + A, or
B + B) placed at the end of each arm. A 10 min retention trial, with
the objects (A + B) (second trial) occurred 2 h later. The amount of
exploration time each animal spent on objects A and B during the acqui-
sition trial varied between 5 and 20 s, depending on the individual
mouse. Total exploration time between the 2 objects when calculated
for each individual animal indicated the absence of the object prefer-
ence bias (Fig. 1C) (n = 5–9 per group). During the retention trial, the
times that the animal took to explore the new object (tn) and the old
object (to) were recorded. A discrimination index (DI) was deﬁned as
(tn− to) / (tn + to). In order to avoid further object preference bias,Fig. 1. Peripheral metabolic parameters in HFD-fedWT and APP/PS1mice. (A) Bodyweight, (B)
lesterol in 6-month-old animals (n= 5–12 independent samples per group). (C) Intraperitonea
5-12 independent samples per group). For the ITT and the IP-GTT, AUC data were calculated fro
the student's t-test,where $ denotes p b 0.05, $$ denotes p b 0.01, $$$ denotes p b 0.001; regular
AC: APP/PS1 control diet,WH: Wild-type high-fat diet, AH: APP/PS1 high-fat diet; open bar: chobjects A and B were counterbalanced so that half of the animals in
each experimental group were ﬁrst exposed to object A and then to
object B, whereas the other half were exposed to object B ﬁrst, and
then to object A. The maze, the surface, and the objects were cleaned
with 96° ethanol between animals, so as to eliminate olfactory cues.2.5. RNA extraction and quantiﬁcation
Total RNA was isolated from the hippocampi of wild-type and APP/
PS1 transgenic mice utilizing Trizol-based extraction (Life Technologies
Corporation; Carlsbad, Ca, USA), as described previously [34]. Brieﬂy,
the tissuewas homogenized in the presence of Trizol reagent (Life Tech-
nologies Corporation; Carlsbad, CA, USA). Chloroform was added and
the RNA was precipitated from the aqueous phase with isopropanol at
4 °C. RNA pellet was reconstituted in RNAse-free water, with the RNA
integrity determined by Agilent 2100 Bioanalyzer (Agilent Technolo-
gies; Santa Clara, CA, USA).2.6. Real-time-PCR
First-strand cDNA was reverse transcribed from 2 μg of total RNA
using the High Capacity cDNA Reverse Transcription kit, according to
manufacturer's protocol (Applied Biosystems). Each sample was
analyzed in duplicate for each target. TaqMan probes (Applied
Biosystems), as detailed in Table 2, were used to determine transcrip-
tion levels of individual genes. Reaction was performed on the
StepOnePlus Real Time PCR system (Applied Biosystems; Carlsbad, CA,
USA) and the values were normalized to gapdh and tbp.fasting blood glucose , fasting serum insulin levels ELISA, total blood triglycerides and cho-
l glucose (16 hour fast) and insulin (4 hour fast) tolerance tests in 6-month-oldmice (n=
m the timepoint 0 till the end of the experiment. (Statistical analysis was performedwith
2-way ANOVA,where& denotes p b 0.05, &&denotes p b 0.01)WC:Wild-type control diet,
ow, closed bar: high-fat diet.
Table 1
A list of antibodies used for immunoblotting and immunoﬂuorescence.
Protein Antibody
Akt #9272 (Cell signaling)
pAkt (S473) #4060P (Cell signaling)
CDK5 Sc-173 (Santa Cruz biotech)
pCDK5 (Y15) ab63550 (Abcam)
ERK1/2 #9102 (Cell signaling)
pERK1/2 (T202/Y204) #9101 (Cell signaling)
GSK3B #9315(Cell signaling)
pGSK3B (Y216) Ab74754 (Abcam)
IDE Ab32216 (Abcam)
IRβ Sc-20739 (Santa Cruz biotech)
pIRβ (Y1150/1151) Sc-81500 (Santa Cruz biotech)
IRS1 #2382 (Cell signaling)
pIRS1 (S612) #2386S (Cel signaling)
IRS2 Sc-1555 (Santa Cruz biotech)
pIRS2 (S723) Ab 3690 (Abcam)
JNK #9252 (Cell signaling)
pJNK (Y183/T185) #9251 (Cell signaling)
Neprelysin Ab951 (Abcam)
NRF1 Sc-28379 (Santa Cruz biotech)
OXPHOS MS604 (MitoSciences)
p35 #2680(Cell signaling)
PGC1A 101707 (Cayman chemical)
PPARa Ab8934 (Abcam)
PPARg #2430 (Cell signaling)
TAU AHB0042 (Biosource)
pTAU (S404) 44748G (Life Technologies)
TFAM DR1071b(Calbiochem)
GAPDH MAB374 (Millipore)
Thioﬂavin S Thioﬂavin S (Sigma-Aldrich)
2nd –ary Anti-Mouse 170-5047 (Biorad)
2nd –ary Anti-Rabbit NA934V (GE Healthcare)
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Slides were allowed to defrost at room temperature and then were
rehydrated with Phosphate-buffered saline (PBS) for 5 min. Later, the
brain sections were incubated with 0.3% Thioﬂavin S (Sigma-Aldrich;
St. Louis, MO, USA) for 20 min at room temperature in the dark. Subse-
quently, these were submitted to washes in 3-min series: with 80%
ethanol (2 washes), 90% ethanol (1 wash), and 3 washes with PBS. Fi-
nally, the slides were mounted using Fluoromount (EMS), allowed to
dry overnight at room temperature in the dark, and stored at 4C.
Image acquisition was performed with an epiﬂuorescence microscope
(BX41; Olympus, Germany).For plaque quantiﬁcation, similar andTable 2
A list of Taqman probes used for real-time PCR analysis.
GENE TaqManProbe
app Mm01344172_m1
essra Mm00433143_m1
gapdh Mm99999915_g1
igf1 Mm01228180_m1
igf2 Mm00439564_m1
igfbp2 Mm00492632_m1
igf1r Mm00802831_m1
ins1 Mm01950294_s1
insr Mm01211875_m1
irs1 Mm01278327_m1
irs2 Mm03038438_m1
nrf1 Mm01135606_m1
nrf2 (nfe2l2) Mm00477784_m1
Ppara Mm00440939_m1
pparg Mm01184322_m1
ppargc1a Mm01208835_m1
prkaa1 Mm01296700_m1
prkaa2 Mm01264789_m1
tbp Mm00446971_m1
tfam Mm00447485_m1comparable histological areas were selected, focusing on having the
hippocampus and the whole cortical area positioned adjacently [35].
2.8. Immunoblot analysis
Aliquots of hippocampal homogenates containing 15 mg of protein
per sample were analyzed using the Western blot method. In brief,
samples were placed in a sample buffer (0.5 m Tris–HCl, pH 6.8, 10%
glycerol, 2%(w/v) SDS,5%(v/v) 2-mercaptoethanol, 0.05% bromophenol
blue) and denatured by boiling at 95–100 °C for 5 min. Samples were
separated by electrophoresis on 10–15% acrylamide gels. Following
this, the proteins were transferred to PVDF sheets using transblot appa-
ratus. Membranes were blocked overnight with 5% non-fat milk
dissolved in TBS-T buffer (50 mM Tris; 1.5% NaCl, 0.05% Tween 20,
pH 7.5). They were then incubated with primary antibodies, as detailed
in Table 1. After O/N incubation, blots were washed thoroughly in TBS-T
buffer and incubated for 1 h with a peroxidase-conjugated IgG second-
ary antibody (1:2000). Immunoreactive protein was detected using a
chemiluminescence-based detection kit. Protein levels were deter-
mined by densitometry, using Chemidoc XRS+ Molecular Imager
detection system (Bio-Rad Laboratories Inc.; Hercules, CA, USA)), with
ImageLab image analysis software. Measurements are expressed as
arbitrary units. All results are normalized to GAPDH, unless stated
otherwise.
2.9. Measurement of β-amyloid peptides in cortical tissues by ELISA
Soluble and insoluble β-amyloid (βA) βA1–40 and βA1–42 were mea-
sured in cortical extracts employing the commercially available mouse
and human ELISA kits (Cat # KMB3481, KMB3441, KHB3481 and
KHB3441; Invitrogen, Camarillo, CA, USA) according to manufacturer´s
guidelines. The soluble fraction was separated by centrifuging the
samples for 10 minutes at 4000xg. The pellets containing insoluble Aβ
peptides were solubilized in a 5 M guanidine HCl/50 mM Tris HCl solu-
tion by incubating for 3.5 hours on an orbital shaker at room tempera-
ture in order to obtain insoluble fraction. Data obtained from the
cortical homogenates are expressed as picograms of Aβ content permil-
ligrams of total protein (pg/mg).
2.10. Data analysis
All data are presented as means ± SEM, and differences are consid-
ered signiﬁcant at p b 0.05. Differences between samples/animals were
evaluated using student's t-test, and either one-way or 2-way ANOVA,
with Tukey's post-hoc test. Both the statistical analysis and the graphs
presented here were created with the GraphPad InStat software V5.0
(GraphPad Sofware Inc., San Diego, CA, USA).
3. Results
3.1. HFD treatment increases body-weight gain, insulin and triglycerides
levels in blood and provokes impaired glucose and insulin tolerance in both
WT and APP/PS1 mice
In order to determine the effects of a high-fat hypercaloric diet on
metabolic parameters in a mouse model of AD, male WT and APP/PS1
animals were fed either standard chow or a HFD. Mice were divided
into 4 groups (n = at least 10 per group): chow-fed WT control (WC),
HFD-fed WT (WH), chow-fed transgenic APP/PS1 (TC) and HFD-fed
APP/PS1 (TH). Treatment commenced at the time of weaning
(21 days) and lasted until the animals reached 6 months of age. This
speciﬁc time point was chosen as at six months-old APP/PS1 mice pres-
ent with AD-like neuropathology, including readily detectable βA
plaques and memory loss [33] (Fig. 2). As expected, HFD treatment
produced progressive diet-induced obesity, with body weight at com-
pletion of the experiment reaching 144% in WH vs. WC (P b 0.0001),
Fig. 2. (A) The results of the 2-object Novel Object Recognition test (NOR), demonstrating signiﬁcant memory loss as a result of a HFD treatment in 6 month-old wild-type, as well as in
chow-fed andHFD-fed APP/PS1 animals, compared to chow-fedwild-typemice (n=7–12 independent samples per group). (B)HippocampalmRNA expression of the appwith the probe
recognizing both mouse and human forms of app in 6-months-old mice (n = 10-12 independent samples per group, with 3 technical replicates per sample). (C) Concentrations of the
soluble and insoluble human βA1–40 and βA1–42 peptides in the cortical extracts in chow- and HFD-fed 6-month-old APP/PS1 mice, expressed as pg/mg of total protein as determined
by ELISA (n = 5–8 independent samples per group, with 3 technical replicates per sample). (D) Immunoﬂuorescence analysis of β-amyloid plaque numbers in the brains of 6-month-
old WT and APP/PS1 mice. No plaques were observed in WT animals (n = 4–6 independent samples per group, with at least 5 slices analyzed per sample). Hoechst staining in blue /
Thioﬂavin S staining in green (Statistical analysis was performed with the student's t-test, where $ denotes p b 0.05, $$ denotes p b 0.01; regular 2-way ANOVA, where & denotes
p b 0.05, && denotes p b 0.01); open bar: chow, closed bar: high-fat diet.
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accompanied by fasting hyperinsulinemia, with plasma insulin concen-
trations of 6.88 pM/ml inWH (1.92 inWC; P= 0.0484) and 8.92 pM/ml
in TH (2.44 in TC; P = 0.0332) (Fig. 1B). An additional sign pointing to
the possible presence of metabolic syndrome in 6-months-old HFD-
fed mice was an increase in fasting triglycerides levels with 146 mg/dl
in WH (96 in WC; P b 0.001) and 202 mg/dl in TH (123 in TC; P =
0.0119). Interestingly, a 2-way ANOVA demonstrated signiﬁcant differ-
ences betweenWT and APP/PS1 groups as a whole, with higher triglyc-
erides concentrations in transgenic animals, suggesting exacerbated
phenotype in AD-like mice (Fig. 1B). Fasting blood glucose levels
support this observation, as the HFD treatment resulted in a signiﬁcant
increase of this parameter in TH vs. TC group (136 vs 76 mg/dl; P =
0.0046), but not in WH vs. WC (106 vs 84 mg/dl; P = 0.1452). Fasting
blood cholesterol levels were not affected in any of the groups (Fig. 1B).
As our initial screening has not only demonstrated clear alterations
in peripheral glucose metabolism in response to HFD, but also signiﬁ-
cant differences between the WT and APP/PS1 animals, we performed
additional glucose and insulin tolerance tests. Predictably, IP-GTT has
shown impaired glucose tolerance in 6-months-oldWH and AH groups,
when compared to their respective controls (P= 0.02 and P= 0.0436)
(Fig. 1C). The results of the ITT were intriguing. While the test results
indicated impaired insulin tolerance in both WH and AH (P = 0.0106
and P = 0.0346) we, once again, detected a more severe phenotype in
an APP/PS1 model (P = 0.0239, with 2-way ANOVA) (Fig. 1C). Taken
together, our data indicate a possible acceleration of a HFD-induced
peripheral metabolic phenotype in APP/PS1 animals compared to con-
trol mice. In the following steps, we proceeded to study the effects of
HFD on CNS and attempted to identify molecular pathways related to
insulin metabolism in the brain, with a particular focus on hippocampal
metabolic and insulin signaling.3.2. High-fat diet contributes to increased cerebral β-amyloid levels and
memory loss
We have employed a 2-object Novel Object Recognition (NOR) test
as a means of evaluating the impact of HFD on cognitive performance.
Interestingly, our results demonstrate that HFD treatment has a signiﬁ-
cant impact onmemory function in both theWT and transgenic animals
(Fig. 2A). In order to determine if the resulting memory loss is depen-
dent on the increased cerebralβA load, we havemeasured hippocampal
expression of the APP, cortical levels of the βA1-40 and βA1-42 and
assessed the numbers of senile plaques in the brain.
Because APP/PS1 mouse model expresses a human form of the APP
and the βA, it is necessary to quantify the combined expression of
both endogenous and transgenic protein. At the mRNA level, a probe
recognizing both human and mouse versions of app was selected for
Real-time PCR analysis. We have detected approximately a 2-fold
increase in app transcripts in the hippocampal extracts of APP/PS1
mice, compared toWT controls (Fig. 2B). Hypercaloric diet did not inﬂu-
ence mRNA expression of this target in either group. Elevated levels of
soluble and insoluble forms of βA1-40 and βA1-42 peptides were detect-
ed in cortical homogenates of APP/PS1 animals. However, HFD treat-
ment resulted in a signiﬁcant increase in insoluble βA1-42 levels only,
and only in TH versus TC group (~266 compared to ~195 ng/mg)
(Table 3 and Fig. 2C). Surprisingly, this increase did not have an effect
on the total number of plaques in the hippocampal and cortical areas
of the brain (Fig. 2D). Furthermore, there appeared to be an increase
in the concentrations of the soluble βA1-42 in WH animals, but it only
affected a subset of this group, rendering the data unsuitable for statis-
tical analysis (Table 3). Thus, our results suggest that alterations in cere-
bral amyloid levels do not play a critical role in HFD-induced memory
loss in 6-month-old mice.
Table 3
Concentrations of the soluble and insoluble mouse and human βA1–40 and βA1–42 peptides in the cortical extracts in chow- and HFD-fed 6-month-old wild-type and APP/PS1 mice,
expressed as pg/mg of total protein as determined by ELISA (n = 5–8 independent samples per group, with 3 technical replicates per sample). (Statistical analysis was performed with
the Student's t-test; ± is S.E.M.).WC: Wild-type control diet, AC: APP/PS1 control diet,WH: Wild-type high-fat diet, AH: APP/PS1 high-fat diet, m: mouse, h: human, t: total (mouse +
human), p: p value (t-test) N/A: not applicable, N/D: not detected.
Sol. (pg/mg) m βA 40 h βA 40 t βA 40 m βA 42 h βA 42 t βA 42
WC N/D N/A N/A 10 ± 10 N/A 10 ± 10
WH N/D N/A N/A 1132 ± 632 N/A 1132 ± 632
AC N/D 649 ± 262 649 ± 262 1120 ± 706 1088 ± 168 2208 ± 863
AH N/D 879 ± 260 879 ± 260 1976 ± 1121 1244 ± 266 3220 ± 1346
WC vs WH (p) N/A N/A N/A 0.1431 N/A 0.1431
AC vs AH (p) N/A 0.558 0.558 0.5215 0.588 0.5305
WC 460 ± 158 N/A 460 ± 158 6 ± 6 N/A 6 ± 6
WH 331 ± 17 N/A 331 ± 17 270 ± 270 N/A 270 ± 270
AC 1276 ± 320 14075 ± 5195 15352 ± 4231 1722 ± 655 193310 ± 24590 194688 ± 24396
AH 1350 ± 190 27338 ± 5954 28688 ± 6138 2502 ± 633 263797 ± 18173 265882 ± 18194
WC vs WH (p) 0.3878 N/A 0.3878 0.3024 N/A 0.3024
AC vs AH (p) 0.8467 0.1476 0.1114 0.4245 0.043* 0.041*
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hippocampus
We evaluated mRNA expression proﬁles of preproinsulin 1 (Ins1),
insulin receptor (Insr), insulin receptor substrates 1 (Irs1) and 2 (Irs2),
insulin-like growth factor I (Igf1), and IGF receptor (Igfr) in the hippo-
campus of 6 months-old mice (Fig. 3A). A modest increase in ins1
transcripts was accompanied by a small but signiﬁcant reduction in
insr and igfr levels in the TH vs. TC group, while HFD treatment did not
have an effect on these molecules in WT brains. Conversely, igf1 was
upregulated inWHvs.WC group, but remained unchanged in transgen-
ic animals. We did not detect signiﬁcant differences in total IRS1 and
IRS2 expression in any of the groups, both at the mRNA and protein
levels (Fig. 3A, B). As post-translational modiﬁcations and especiallyFig. 3. (A)mRNA expression proﬁle (n= 4–6 independent samples per group, with 3 technical
quantiﬁcation (n=4–6 independent samples per group) ofmolecules related to proximal insul
APP/PS1 mice. Mouse pSer612-IRS1 and pSer723-IRS2 correspond to human pSer616-IRS1 and p
p b 0.05; $$ denotes p b 0.01; regular 2-way ANOVA, where & denotes p b 0.05, && denotes pligand-mediated tyrosine1150/1151 autophosphorylation of the signal-
transducing catalytic β-subunit of IR play a major role in receptor
activation, we have measured protein levels of both total IRβ and
pTyr1150-1151-IRβ. Immunoblotting analysis revealed no changes in the
ratios between the phosphorylated and total IRβ protein in the hippo-
campal extracts at 6 months of age (Fig. 3B), suggesting that receptor
functionality is unaffected. Functional IR is necessary for downstream
signaling which is controlled in large part by IRS1 and IRS2 adaptor
molecules. Autologous (insulin-mediated) and insulin independent
Ser/Thr phosphorylations of IRS may both potentiate and attenuate IR
signaling. Mouse pSer612-IRS1 and pSer723-IRS2 (corresponding to
human pSer616-IRS1 and pSer731-IRS2) are amongst the better known
negative regulators of the IR-IRS pathway. Thus, an insulin-dependent
increase in the phosphorylation state of these residues may lead toreplicates per sample) and (B) representative GAPDH-normalized immunoblot images and
in signaling in the hippocampal extracts of chow- andHFD-fed 6-month-oldwild-type and
Ser731-IRS2 (Statistical analysis was performed with the student's t-test, where $ denotes
b 0.01); open bar: chow, closed bar: high-fat diet.
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ences in IRS1 phosphorylation, however, our data demonstrated a
signiﬁcant increase in pSer723-IRS2 in WH vs. WC (P = 0.039) and in
APP/PS1 vs. WT (2-way ANOVA, P = 0.0078) mice (Fig. 3b), indicating
a potential role of IRS2 in response to both the hypercaloric diet treat-
ment and in AD-like phenotype.
3.4. Effects of HFD on signaling kinases and tau phosphorylation
Having determined that the proximal insulin signaling is likely
perturbed in the hippocampi of HFD-exposed and APP/PS1 transgenic
animals, we turned our attention to the signaling kinases implicated
both in insulin signaling and senile plaque formation. Apart from their
diverse cellular roles, these kinases (except for CDK5) have also been
shown to phosphorylate IRS proteins directly, thus modulating the
activity of these adaptor molecules. We measured protein levels of
pSer473-Akt, pTyr216-Gsk3β, pThr183/pTyr185-JNK1, pThr202/pTyr204-
ERK1/2, pTyr15-CDK5 and its activatormolecule p35 in the hippocampal
extracts of 6-month-old animals. All of the abovementioned phosphor-
ylations result in the activation of the respective kinases. Interestingly,
we have observed signiﬁcant differences in the activation state in all
of the kinases tested when compared to at least one of the groups
(Fig. 4). For example, ERK1/2 and CDK5/p35 were overactivated in
WH vs. WC group only, while JNK1 activity was enhanced in WH vs.
WC and TH vs. TC hippocampi. Basal GSK3β activation was higher in
the TC vs. WC groups, with the HFD resulting in additional activation
in WH group only. In contrast, Akt activity was inhibited in all of the
groups when compared to WC (WH vs. WC; TC vs WC; TH vs. TC, as
well as in APP/PS1 vs. WT – 2-way ANOVA, P = 0.0085). As kinase-
mediated Tau hyperphosporylation is one of the principal diagnostic
criteria of AD, we have also measured the phosphorylation state of the
Tau protein at Ser404. HFD treatment resulted in a signiﬁcant increase
in pSer404-Tau in theWH vs. WC group, an increase which was compa-
rable to the levels observed in the hippocampus of the APP/PS1 animalsFig. 4. Representative GAPDH-normalized immunoblot images and quantiﬁcation (n= 4–6 ind
campal extracts of chow- and HFD-fed 6-month-old wild-type and APP/PS1 mice. (Statistical
p b 0.01; regular 2-way ANOVA, where & denotes p b 0.05); open bar: chow, closed bar: high-(Fig. 4). Collectively, our data suggest that the HFD treatment shares
some of the features of the distal insulin signaling abnormalities
observed in AD-like model.
3.5. Amyloid degrading enzymes (ADE) and HFD
Peripheral hyperinsulinemia and insulin resistance disrupts insulin
transport into the CNS, resulting in the reduction of brain insulin levels.
Under the normal circumstances, excess insulin is removed by Insulin
Degrading Enzyme (IDE), increased expression of which forms a part
of a negative feedback loop triggered by insulin itself. Thus, low local
insulin levels will result in the reduced expression of IDE. As expected,
we have observed a signiﬁcant reduction in the protein levels of IDE in
the hippocampi of both WH and TH mice (Fig. 5). However, IDE may
also participate in β-amyloid clearance, and the reduction in its levels
may potentially exacerbate APP/PS1 phenotype. Neprilysin is another
well-known ADE that had been implicated in Aβ degradation. Interest-
ingly, we detected a signiﬁcant upregulation of neprilysin levels in TH
vs. TC group (Fig. 5), suggesting a possible compensatory mechanism
to counteract elevated amyloid load in HFD-treated APP/PS1 mice.
3.6. Mitochondrial metabolism is altered in the hippocampi of HFD-fed WT
and APP/PS1 mice
So far, we have mainly focused on the insulin route and have not
discussed the implications of altered insulin signaling onmitochondrial
homeostasis. As mitochondria are the principal organelles involved in
cell metabolism, wemeasured hippocampal mRNA and protein expres-
sion levels of a number of molecules associated with mitochondrial
energy status and biogenesis. We did not detect changes in the mRNA
expression ofα- catalytic subunits of one of themajor kinases activated
in response to ATP depletion – AMPK (Prkaa1 and Prkaa2 levels were
not affected in any of the groups). However, we observed a marginal
but signiﬁcant reduction in response to HFD in a key transcriptionalependent samples per group) of molecules related to distal insulin signaling in the hippo-
analysis was performed with the student's t-test, where $ denotes p b 0.05; $$ denotes
fat diet.
Fig. 5. Representative GAPDH-normalized immunoblot images and quantiﬁcation (n= 4–6 independent samples per group) of enzymes implicated in β-amyloid degradation in the hip-
pocampal extracts of chow- and HFD-fed 6-month-oldwild-type and APP/PS1mice. (Statistical analysiswas performedwith one-way ANOVAwith Tukey's post-hoc test, where * denotes
p b 0.05, ** denotes p b 0.01); open bar: chow, closed bar: high-fat diet.
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lated byAMPK (ppargc1awas reduced in APP/PS1 vs.WT groups; 2-way
ANOVA, P = 0.0144; PGC-1αwas reduced inWH vs. WC and TH vs. TC,
P = 0.0044 and P = 0.0022, respectively) (Fig. 6A, B).
We have also determined the expression levels of PGC-1α co-
regulated transcription factors, including peroxisome proliferator-
activated receptors α (PPAR-α) and γ (PPAR-γ), mRNA and protein
levels of which remained unchanged (Fig. 6A, B). Differences in the
mRNA expression of the nuclear respiratory factors 1 (nrf1) and 2
(nrf2) between the groups were very small, even though statistically
signiﬁcant, and were comparable to the changes observed in estrogen-Fig. 6. (A)mRNA expression proﬁle (n= 4–6 independent samples per group, with 3 technical
quantiﬁcation (n=4–6 independent samples per group) ofmolecules related to distal insulin s
6-month-old wild-type and APP/PS1mice. (Statistical analysis was performedwith the student
bar: chow, closed bar: high-fat diet.related receptor α (esrra) and mitochondrial transcription factor A
(tfam) transcripts (Fig. 6A). At the protein level, we detected a signiﬁ-
cant reduction of TFAM in WH vs. WC and TH vs. TC groups (Fig. 6B).
In addition, we evaluated mitochondrial function impairment via
immunoblotting analysis of OXPHOS complexes. Our results demon-
strated signiﬁcant reduction in OXPHOS I, II, III and IV in the hippocampi
of 6-months-old WH vs. WC mice. All of the OXPHOS complexes were
down regulated in the basal state in TC vs. WC animals, and were not
further reduced in response to HFD treatment (Fig. 7). Taken together,
our data indicate signiﬁcant perturbations in cellular energy metabo-
lism in the brains of HFD-treated and APP/PS1 mice.replicates per sample) and (B) representative GAPDH-normalized immunoblot images and
ignaling andmitochondrial homeostasis in the hippocampal extracts of chow- andHFD-fed
's t-test, where $ denotes p b 0.05; regular 2-way ANOVA,where & denotes p b 0.05); open
Fig. 7. Representative GAPDH-normalized immunoblot images and quantiﬁcation (n = 4–6 independent samples per group) of mitochondrial OXPHOS complexes in the hippocampal
extracts of chow- and HFD-fed 6-month-old wild-type and APP/PS1mice. (Statistical analysis was performedwith the student's t-test, where $ denotes p b 0.05, $$ denotes p b 0.01; reg-
ular 2-way ANOVA, where & denotes p b 0.05, && denotes p b 0.01); open bar: chow, closed bar: high-fat diet.
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The original “amyloid cascade” hypothesis postulated over 20 years
ago in a seminal Science paper by Hardy and Higgins [10] has undoubt-
edly led to major breakthroughs in understanding the pathophysiology
of AD. At its core, the hypothesis deﬁned the cascade as a sequence of
events starting from abnormal β-amyloid peptide processing leading
to β-amyloid deposition, tau phosphorylation and neuroﬁbrillary tangle
formation, all of which ultimately result in cellular dysfunction and
neuronal death [11]. Since then, signiﬁcant research efforts on the part
of academic labs and the pharmaceutical industry have largely focused
on the amyloid cascade as the principal target for AD treatment. Unfor-
tunately, none of the molecules that reached Phase II and III clinical
trials targeting this pathway have proven to be more effective than
placebo at treating AD (reviewed in [36]).Mounting criticismof the am-
yloid cascade hypothesis has recently prompted John Hardy himself to
address the issues plaguing AD drug development [37]. The general fail-
ure of the amyloidocentric approach in pharmaceutical development
strongly suggests that the β-amyloid is unlikely to be solely responsible
for AD progression.
It has been long suspected that mitochondria play a signiﬁcant role
in neurodegenerative diseases [38–40]. By 2004, Swerdlow & Khan
[41] proposed a comprehensive model which takes into account mito-
chondrial alterations occurring during the course of AD. The “mitochon-
drial cascade” hypothesis suggests that the cause and effect relationship
in AD are reversed when pitted against an “amyloid cascade” hypothe-
sis. The theory implies that the damage to themitochondria occurs prior
to the β-amyloid accumulation. This view has recently been expanded
[42–44] and is supported by a number of studies (reviewed in [45])
which classify AD as a primarily metabolic disorder. According to this
view, dementia develops as a result of the diminished ability of the
brain to efﬁciently utilize the available glucose, leading to reduced
neuronal plasticity which affects cerebral capacity to form and retain
memories.
In the present paper, we present results that reinforce the hypothe-
sis that AD may be viewed as a metabolic disorder, with the disease
neuropathology at least partially related to insulin signaling failure
and energy depletion in hippocampal neurons. Our data notwithstand-
ing, before we continue the discussion regarding the implications of
insulin signaling and mitochondrial regulation on hippocampal memo-
ry, we would like to address some of the discrepancies in peripheral
metabolic parameters in our results compared to previously published
studies. Ramos-Rodriguez and colleagues recently reported that a simi-
lar HFD treatment did not result in an increase in basal fasting blood
glucose levels, nor in plasma triglycerides, but instead increased plasma
cholesterol in 6 months-old APP/PS1 animals [46]. Our data clearlydemonstrate elevated basal blood glucose in TH group, an increase in
total blood triglyceride levels in WH vs. WC and in TH vs. TC groups,
and no changes in cholesterol levels. Regarding blood glucose measure-
ments, our methodology is very similar with 16 hours-long fast applied
in both studies. However, the glucose values approximating 60 mg/dl
detected by Ramos-Rodriguez et al, suggest that the measurements
were taken at room temperature, which may explain the observed
differences in the basal glucose levels in WC animals (~80 mg/dl in
our study), as our tests were conducted at 28-29C [32]. As for the differ-
ences in cholesterol and triglycerides levels, these can be easily
explained by the different diets used (60% Kcal obtained mainly from
animal fat (lard) in Ramos-Rodriguez et al, vs. 45% Kcal mainly from
hydrogenated coconut oil (vegetable fat) in our study). Interestingly, in-
creases in plasma insulin levels in mice treated with either diet were
comparable. Taken together, our data indicate that metabolic syndrome
is indeed present in our model.
The connection between AD, obesity and type-2 diabetes has been
known by epidemiologists for some time now. In fact, as early as
2004, in a study carried out at the Mayo clinic, investigators reported
either impaired fasting glucose or diabetes in 81% of human subjects
suffering from AD [47]. However, it is only recently that we are begin-
ning to understand the pathophysiological processes linking peripheral
metabolic abnormalities and neuronal dysfunction. Defective insulin
signaling and mitochondrial redox imbalances appear to play a major
role in the development of both the metabolic syndrome and AD.
Crucially, it has been suggested that the insulin-dependent signaling
in the brainmay potentially be regulated via the pathways independent
of its glucoregulatory functions in the periphery [48–50]. In the present
study, we compared molecular pathways involved in memory loss in
mice as a result of a HFD treatment, with animals which lose memory
as a consequence of an APP/PS1 genotype. It was reported previously
that the continuous exposure of juvenile (3-weeks-old) mice to a HFD
causes relational memory loss (hippocampus-dependent) in a signiﬁ-
cant number of animals by 5 months of age [51]. We have chosen a
similar experimental approach, but have focused on 6-months-old
animals, with our data indicating that virtually all HFD-fed WT mice
demonstrate pronounced memory loss at this age, as measured by
NOR test. Importantly, 6-months-old APP/PS1 control animals present
with similar memory deﬁcits when compared to WH group. This has
permitted us to make direct comparisons between the treated and
untreated WT and APP/PS1 animals. One of the intriguing ﬁndings in
our study is that the HFD-induced memory loss appears to be indepen-
dent of the levels of cerebralβ-amyloid peptide inmice not predisposed
to abnormal βA processing (even though we detected a signiﬁcant
increase in insoluble βA1-42 levels in cortical homogenates in TH vs. TC
group).
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which includes peripheral hyperinsulinemia, peripheral insulin resis-
tance, peripheral and central hyperglycemia and dyslipidemia among
others. So, what are the components of metabolic syndrome that result
in memory loss in HFD-fed WT animals? Assuming that the insulin is
involved, we need to consider that one of the key differences in brain
insulin signaling between AD and diet-induced obesity is the availabili-
ty/quantity of insulin hormone in the brain. Diet-induced obesity
results in the disruption of the Blood-Brain-Barrier (BBB), which limits
receptor-mediated insulin transport to the CNS. Therefore, somewhat
counterintuitively, peripheral hyperinsulinemia actually provokes insu-
lin deﬁciency in the brain [52–56]. On the other hand, in AD, cerebral in-
sulin resistance has been widely implicated in disease pathogenesis
(reviewed in [48]). While the distinction between insulin deﬁciency
and insulin resistancemay seem trivial to some authors in the neurosci-
ence ﬁeld (to the point that a large number of studies use both terms
interchangeably), it may have a signiﬁcant impact on potential treat-
ment strategies. For example, in an insulin-resistant (at the CNS level)
non-obese AD patient, it may actually be beneﬁcial to choose an oral
anti-diabetic drug treatment as a means for improving AD symptoms.
Conversely, the same treatment in an obese patient may not have the
desired effects due to the inability of the extra insulin to cross BBB, in
which case the intranasal administration may provide better outcomes.
Regardless of the root cause, if we consider insulin signaling perturba-
tions to be one of the contributors to memory loss and AD-like
symptoms in our model, then both the proximal and distal insulin sig-
naling pathways should be altered in the hippocampal region. Proximal
insulin signaling consists of an insulin-IR/IGF-1R-IRS axis, whereby the
binding of the insulin to the extracellular alpha subunit of the IR or
IGF-1R initiates a series of Tyr autophosphorylations in the beta subunit,
disinhibiting intracellular Tyr kinase activity towards IRS, thereby
allowing these adaptor molecules to interact with a large number of
targets. Once activated, IRS1 and 2 are further regulated via a highly
complex mechanism involving multiple Ser/Thr kinases, which can
phosphorylate the tail regions of IRS molecules at over 50 Ser/Thr resi-
dues. Unlike Tyr phosphorylation by the IR, which activates IRS, modiﬁ-
cations at Ser/Thr residues are capable of both promoting and inhibiting
downstream IRS-mediated signaling [57]. As previously mentioned,
cerebral insulin resistance has been implicated in AD pathogenesis.
Such a resistance may stem from defects in IR itself [58], or may be
mediated via negative regulation of the IRS. Our data suggest that the
IR is functional in the hippocampi of 6 months-old HFD-treated WT
and APP/PS1 mice. Furthermore, we have also detected a signiﬁcant in-
crease in igf1 transcripts in WH vs. WC animals, possibly in response to
cerebral insulin deﬁciency. We then considered the possibility that the
downregulation of the IRS pathway, via inhibitory Ser/Thr phosphoryla-
tion, may attenuate downstream insulin signaling. As it is nearly impos-
sible to determine the phosphorylation state of all of the 50+ Ser/Thr
residues of the IRS molecules within the scope of a single paper, we
have performed immunoblotting analysis of mouse pSer612-IRS1 and
pSer723-IRS2 (corresponding to human pSer616-IRS1 and pSer731-
IRS2). Elevated levels of pSer616-IRS1 were previously detected in
neurons of AD patients and were associated with insulin resistance
[59], and an increase in pSer723-IRS2 protein levels was observed in
dorsal root ganglia neurons of diabetic mice [60]. As indicated in our
ﬁndings, therewere nodifferences in pSer612-IRS1 for any groups. How-
ever, we detected a signiﬁcant increase in hippocampal pSer723-IRS2 in
WH, TC and TH mice. While our analysis is by no means exhaustive, it
does support the hypothesis that the hippocampus-dependentmemory
loss is, at least in part, dependent on insulin signaling deﬁciencies.
Ser/Thr phosphorylation of the IRS molecules is mediated by both
insulin-dependent (autologous) and insulin-independent (heterolo-
gous) kinases. Autologous regulation is thought to be the predominant
form of downstream insulin-mediated signaling under physiological
conditions. In a disease state, however, preferential activation of the
heterologous pathway may contribute to the underlying pathology.Cellular stress and/or proinﬂammatory phenotype may cause inappro-
priate Ser/Thr modiﬁcations of IRS, which may result in the “hijacking”
of the normal physiological route. In the current study, we measured
hippocampal expression of IRS-regulating Ser/Thr kinases, which are
also known to play a role in neurodegenerative diseases. These include
autologous (Akt, ERK 1/2), heterologous capable of phosphorylating IRS
in the basal cellular state (AMPK, GSK3β), as well as heterologous
kinases activated in response to cellular stress and sympathetic activa-
tion (JNK1) [57].
4.1. Insulin-IRS-Akt-GSK-3β pathway
Apart from the involvement of insulin, insulin-relatedmolecules and
their receptors in the cognitive loss observed in HFD-fed animals, we
would like to further discuss key pathways and molecules related to
insulin signaling. This pathway is one of the major regulators of distal
insulin signaling. Activated IRS recruits PI3K, thus activating down-
stream signaling cascade involving 3-phosphoinositide-dependent
protein kinase-1 (PDK1), Akt and GSK-3β. In the context of glucose reg-
ulation, GSK-3β promotes glycogen synthesis, but it is also one of the
principal kinases responsible for Tau phosphorylation [61]. Successful
activation of Akt requires not only phosphorylation at Thr308 by
PDK1, but also additional “priming” at Ser473 residue by mammalian
target of rapamycin (mTOR) complex [62]. The activity of GSK-3β is,
in turn, negatively regulated by phosphorylation at Ser9 residue by
activated Akt, as well as positively regulated by autophosphorylation
at Tyr216 [63]. Our data demonstrate both HFD- and transgene-
dependent decrease in hippocampal pSer473-Akt levels, accompanied
by an increase in activated pTyr216-GSK-3β protein levels in 6-
months-old mice. Furthermore, we have also observed an upregulation
in pSer404-Tau, which suggests abnormalities in IRS-Akt-GSK-3β signal-
ing. These results are in line with previously published postmortem
examinations of the brains of human patients suffering from AD and
diabetes [64].
4.2. AMPK, PPAR and ERK
ERK has been implicated as a key molecule involved in hippocampal
memory consolidation.While directly stimulated by insulin, it may also
be partially activated via IRS-independent mechanisms [57], thus offer-
ing a potentially attractive modulatory target for the pharmaceutical
intervention. ERK acts via ERK/CREB/CBP pathway, activation of which
ultimately results in the transcription of genes required for neuronal
plasticity and long-term potentiation (LTP), in particular. In the brain,
ERK was shown to be positively regulated by AMPK [65], a key energy
sensor in the peripheral tissues, the role of which in the CNS remains
controversial [66]. In addition, activated ERKwas shown to be recruited
(thus activating) to PPARγ, a nuclear receptor and a transcription factor
which activates a number of genes related to insulin sensitivity and
cognition [67]. We did not detect any changes in the α subunit of the
AMPK, nor in PPARα and γ levels, but we did observe an increase in
pThr202/pTyr204-ERK1/2 in response to HFD treatment. Considering
that ERK expression is positively correlatedwithmemory consolidation
our results may seem contradictory, however this is not the case. Feld
et al [68] have recently demonstrated that a minimum threshold of
ERK expression is required to maintain memory function, and that the
aberrant overexpression of ERK protein leads to memory impairment
in a similar manner as ERK deﬁciency.
4.3. JNK1
This stress activated pro-inﬂammatory and pro-apoptotic MAPK has
been previously linked to neurodegeneration and to AD, albeit the
existing evidence for its importance is rather strenuous (reviewed in
[69]). There is much more support for the involvement of JNK1 in
diet-induced obesity and the peripheral insulin resistance (reviewed
Fig. 8. A proposed mechanism whereby insulin signaling and mitochondrial dysregulation contribute to hippocampal phenotype in HFD-fed and AD-like mice. Increased circulating tri-
glyceride levels in response to HFD treatment initially provoke cerebral insulin deﬁciency, which results in the downregulation of the canonical insulin signaling pathway in the hippo-
campus. At the same time, the free fatty acid-mediated increased metabolic stress subverts autologous IR-IRS-Ser/Thr kinase axis signaling, thus favoring heterologous regulation. This
route, once activated, initiates a series of self-propagating events which ultimately lead to insulin resistance in amanner similar to that observed in response to elevated β-amyloid levels.
As functional IR signaling in thehippocampus is, at least partially, regulatingneuronal glucose entry [74], the inhibition of this pathwaymay result in the reduced supply of readily available
energy to themitochondria, affecting neuroplasticity.Mitochondrial OXPHOSmetabolismdeﬁcienciesmay thus be explainedby twopossiblemechanisms: (a) as a direct result of reduced
glucose availability, and (b) as a consequence of decreased mitochondrial biogenesis (PGC1) and/or disruptions to mitochondrial function due to hyperphosphorylated Tau protein and
increased β-amyloid levels.
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pTyr185-JNK1 in the hippocampi of HFD-fed mice, irrespective of the
β-amyloid load, is curious for two reasons. One: it suggests that
hippocampal insulin signalingmay in fact be strikingly similar to the pe-
ripheral phenotype. Two: very high levels of β amyloid, as observed in
6-months-old APP/PS1 control animals, are not sufﬁcient to trigger
elevated JNK1 expression.
4.4. CDK5
Cyclin-dependent kinase 5 (co-activated by p35) does not phos-
phorylate IRS directly, however increased activity of this kinase (and
GSK-3β) contributes to Tau hyperphoshorylation, resulting in neuroﬁ-
brillary tangle formation (reviewed in [71]). We have detected a signif-
icant upregulation of both the CDK5 and GSK-3β kinases in the
hippocampi of HFD-fed WT mice. These data correlate well with the
observed increase in pSer404-Tau.
4.5. PGC-1α
Our data demonstrate a signiﬁcant decrease in insulin signaling and
impaired glucose homeostasis in the hippocampus. As hippocampal
neurons require copious amounts of energy in order to be able to form
and retain memories, such deﬁciencies will likely have an effect on
mitochondrial energy metabolism. Therefore, in the latter part of this
study, we have focused on the pathways related to mitochondrial
biogenesis and OXPHOS pathway.
The peroxisome proliferator-activated receptor-γ coactivator-1α
(PGC-1α) is a transcriptional co-activator which, apart from other func-
tions, plays a critical role in mitochondrial biogenesis. PGC-1α was
previously shown to regulate the expression, either directly or indirect-
ly, of the nuclear respiratory factors 1 (NRF1) and 2 (NRF 2), estrogen-
related receptor α (ESRRa) and mitochondrial transcription factor A
(TFAM) (reviewed in [72]). While we have observed a signiﬁcantreduction in PGC-1α protein levels in response to HFD treatment, and
various statistically signiﬁcant changes in the above mentioned mole-
cules, most of the differences were rather modest in numerical values,
and may or may not represent the behavior of individual targets
under similar experimental conditions. Taken together, however, our
data suggest clear impairments in mitochondrial function. Regarding
the expression of OXPHOS proteins, we detected signiﬁcant decreases
in mitochondrial OXPHOS metabolism in both the HFD-fed WT mice
and in APP/PS1 animals. This ﬁnding is especially signiﬁcant as
OXPHOS deregulation has been previously linked to both the βA and
Tau pathologies in AD brains (reviewed by [73]).
In conclusion, we have demonstrated some parallels between the
hippocampus-dependent HFD-induced memory loss vs. the memory
loss occurring in a mouse model of Alzheimer disease. Our results
indicate that the brain β-amyloid levels seem not to be the primary
cause of the HFD-inducedmemory perturbations. It appears that the re-
ductions in brain insulin signaling and the resulting mitochondrial
dysfunction are among the key culprits leading to cognitive decline in
early-stage AD-like rodent models. A summarized view of our hypothe-
sis is provided in Fig. 8.Disclosure statement
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